

## RP- HPLC METHOD DEVELOPMENT FOR SIMULTANEOUS ESTIMATION OF SITAGLIPTIN PHOSPHATE AND METFORMIN HYDROCHLORIDE IN PHARMACEUTICAL DOSAGE FORM

Shyam Rangari<sup>1\*</sup> and Makarandpatil<sup>2</sup>

<sup>1</sup>Smt. Kishoritai Bhoyar College of Pharmacy,  
Kamptee, Nagpur-44 1905 Maharashtra, India.

<sup>2</sup>KYDSCT's College of Pharmacy,  
Bhusawal-425 201 Maharashtra, India.

### ABSTRACT

Reversed phase high performance liquid chromatography procedure was made and affirmed for the simultaneous estimation of Sitagliptin phosphate (SGP) and Metformin hydrochloride (MFH) in united estimation structure by using UV identifier. Picked adaptable stage was a blend of ACN: Methanol: Phosphate cradle (30:25:45 % v/v) at pH 3 and recurrence picked was 252 nm. Maintenance time of MFH and SGP is 2.36 and 3.39 min. Linearity of the strategy was viewed as 80% to 120% of test obsession with backslide coefficient of 0.9997. This technique was endorsed by ICH rules. Estimation was done by registering zone of the apex and beyond what many would consider possible and quantitation limit (S/N) were 0.16 and 0.46 µg/ml. Present strategy can be applied for the finishes of SGP and MFH in quality control tests, subtleties without impedance of the excipients present and in the breaking down examinations of the medicine.

**Keywords:** Sitagliptin phosphate, Metformin hydrochloride and Liquid Chromatography.

### INTRODUCTION<sup>1,2,3,4,26,35</sup>

Hypoglycemia is a condition wherein your (glucose) level is lower than ordinary. Glucose is your body's principle vitality source. Diabetes treatment and different conditions can cause hypoglycaemia. Disarray, heart palpitations, instability and tension are side effects. Sitagliptin attempts to seriously repress the compound dipeptidyl peptidase 4 (DPP-4). This chemical separates the incretins GLP-1 and GIP, gastrointestinal hormones discharged in light of a dinner. It is used as hypoglycemic specialists<sup>2</sup>. Metformin hydrochloride diminishing the retention from the gastrointestinal tract. Also they can decrease gluconneogenesis while expanding glucose take-up by muscle and fat cells<sup>1,2</sup>. Composing study reveals that single not many RP-HPLC and HPTLC procedures are represented the affirmation of MFH and SGP in Stability-indicating test<sup>3</sup>.

The essential inspiration driving this assessment is to make and support pivoted stage HPLC procedure which is clear, accurate, budgetary, sensitive and specific for quantitation of MFH and SGP in mass and combined portion structures. The made system can be successfully used in routine quality control and for crumbling learns at low centralization of MFG and SGP. Sensible quantifiable test were performed on endorsement data (Fig. 1: Structure of MFH and SGP).

### MATERIALS AND METHODS<sup>5,6,7,8,9,26,35</sup>

#### MATERIALS

Pure sample of Sitagliptin phosphate and Metformin hydrochloride was gotten from Meditab Specialities Pvt. Ltd, (Daman) as a gift test. Methanol was of HPLC grade and purchased from spectrochem Mumbai and other pad salts little of logical assessment. Twofold refined water was used for arranging

of pad. Potassium Dihydrogen phosphate pad plan (25 mM) was organized and was isolated anyway 0.22 channel (Millipore). Tablet meaning of 50 mg SGP and 500 mg MFH were made from MSD Pharmaceuticals {JANUMET}.

#### Equipment

HPLC gear (Waters Corporation) Consisted of model waters - 510 twofold reacting siphons, Water's 486 tunable absorbance UV Detector. Chromatograms were destitute down using Borwin programming outfitted with the structure.

#### Chromatographic condition

Separation was performed on a reversed stage Phenomenex C18 section (250 × 4.6 mm, 5 µm) portion. Versatile stage contained a mixture of ACN: Methanol: Phosphate support (30:25:45 % v/v) at pH 3. Stream rate was changed as per 1ml/min and the wavelength was set to 252 nm, showed up in fig. No. 03.

#### Calibration Curve

Independently precisely gauged amount 2.5 mg of MFH and SGP were broken down in Methanol and volume was made up to 25 ml imprint to make stock arrangement (0.1 mg/ml). The stock standard arrangement was weakened further with versatile stage to get adjustment guidelines in a focus extend 10-60 µg/ml of MFH and 1-6 µg/ml of SGP. Adjustment bend was plotted between top territories of MFH and SGP against convergence of medication (Fig. 2: Calibration curve obtained by MFH and SGP).

#### Analytical Validation<sup>34,35</sup>

Procedure was affirmed by ICH rules. Identity and selectivity of the procedure was assessed by preparing medicine assemblies of MFH and SGP 1000 µg/ml from unadulterated prescription stock and business test stock in picked flexible stage and explored. To choose the accuracy of the proposed system, different degrees of drug obsessions. Different assemblies of unadulterated medicine courses

of action of MFH and SGP (15, 25 and half) were added to a known pre-dissected definition were explored. The recovery of the extra unadulterated prescription was settled. As a bit of precision, repeatability was controlled by taking different degrees of medicine center (same as exactness) organized from new stock game plan and were bankrupt down. Cover day and intra day assortment and bury master assortment inspects were finished to choose widely appealing precision of the procedure. To set up linearity of the proposed technique, six separate game plan of course of action of the OLZ and FLX were set up from the stock game plan and analyzed. ANOVA test (single heading) was performed to choose the assortment between the copies and it relied upon the district of the apex looked for unadulterated prescription concentration during the mimic estimation of the standard plans. Sign to upheaval extent of 3 were taken as cutoff of disclosure (LOD) and sign to noise extent of 10 were taken as limit of quantitation (LOQ). The LOQ trial of MFH and SGP were set up in reproduces (n =5) using same strategy clung to for arrangement gauges and dismembered. Intensity of the procedure was constrained by changing bit of flexible stage by 1%, by changing the pH of potassium dihydrogen phosphate pad by 0.1 units and by working up the seat top, stock game plan reliability of MFH and SGP at room temperature (Fig. 3: Chromatogram obtained by MFH and SGP, showing retention time for MFH – 2.36 min. and SGP – 3.39 min).

## RESULTS AND DISCUSSION

### Analysis of combined dosages Form (Marketed formulation)

Substance of 10 tablets of MFH and SGP were discharged and material proportional to 1 mg of medication (MFH and SGP) were taken to set up an answer of 50 µg/ml in methanol. Last weakening was made with portable stage to acquire focus inside the linearity go. Six duplicates were set up for all definitions.




Fig. 1: Structure of MFH and SGP




Fig. 2: Calibration curve obtained by MFH and SGP




Fig. 3: Chromatogram obtained by MFH and SGP, showing retention time for MFH – 2.36 min. and SGP –3.39 min

Table 1: SPH and MFH calibration curve data

Conc. of SPH (µg/ml)	Conc. of MFH (µg/ml)	Area of SPH	Area of MFH	SD of SPH	SD of MFH
1	10	28243.33	721754	338.85	10468.9
2	20	55489.66	1254589	661.27	38566.3
3	30	82478	1681775	2155.13	1307.02
4	40	113223.33	2123666.66	1774.25	4316.92
5	50	143222	2538375.33	4760.94	926.116
6	60	171473.33	2935590.66	4417.43	2932.17

Each value is average of six determinations

Table 2: Precision data for MFH and SGP developed method

S. No.	Sample	Statistical data	% Estimation		% Recovery	
			MFH	SGP	MFH	SGP
1.	Standard lab. Mixture	Mean	99.95	99.91	628.12	63.11
		S.D.	0.3124	0.3282	0.3644	0.3858
		C.V.	0.1816	0.1949	0.1798	0.2357
2.	Marketed Formulation	Mean	99.98	99.95	626.21	62.45
		S.D.	0.4512	0.5569	0.6147	0.6826
		C.V.	0.2839	0.2402	0.3040	0.3484

Each value is average of three determinations

**Table 3: Repeatability Study for MFH and SGP developed method**

Parameter	Statistical data	% Estimation by RP-HPLC method	
		MFH	SGP
Interday	Mean	100.01	99.99
	S.D.	0.1744	0.2757
	C. V.	0.1090	0.1688
Intraday	Mean	99.94	99.91
	S.D.	0.3702	0.2304
	C. V.	0.8118	0.1946
Different analyst	Mean	99.97	100.03
	S.D.	0.3792	0.3631
	C. V.	0.1553	0.2195

Each value is average of three determinations

**Table 4: Accuracy and Recovery data for MFH and SGP developed method**

Amount Added	Amount Found (mg) of SGP								
	Day 1			Day 2			Day 3		
	Mean	S.D.	%R.S.D	Mean	S.D.	%R.S.D	Mean	S.D.	%R.S.D
Lable claim + 15% = 57.5 mg	57.65	0.32	0.19	57.44	0.55	0.24	57.59	0.27	0.16
Lable claim + 25% = 62.5 mg	63.11	0.38	0.23	62.45	0.68	0.34	62.41	0.74	0.94
Lable claim + 50% = 75.0 mg	75.84	0.36	0.21	75.05	0.38	0.23	75.48	0.27	0.14
Amount Added	Amount Found (mg) of MFH								
	Day 1			Day 2			Day 3		
	Mean	S.D.	%R.S.D	Mean	S.D.	%R.S.D	Mean	S.D.	%R.S.D
Lable claim + 15% = 575 mg	576.08	0.3	0.18	574.5	0.45	0.28	576.8	0.17	0.10
Lable claim + 25% = 625 mg	628.12	0.36	0.17	626.21	0.611	0.304	623.41	0.37	0.81
Lable claim + 50% = 750 mg	756.71	0.26	0.11	751.08	0.3214	0.13	757.12	0.37	0.15

Each value is average of three determinations

**Table 5: System suitability parameters for MFH and SGP developed method**

S.No	MFH		SGP	
	Parameter	Value	Parameter	Value
1	Theoretical plates	4500	Theoretical plates	2500
2	Retention time (min)	2.35	Retention time (min)	3.37
3	Asymmetry	1.05	Asymmetry	1.10

Each value is average of three determinations

## CONCLUSION

For compact stage smoothing out various supports of different pH like ammonium acidic corrosive induction pads, acidic corrosive determination bolsters and different blends of the regular stage (acetonitrile and methanol) close by pad were explored. Change the pad, pH and extension of common dissolvable in various degrees changed the support time of the medicine and uniformity of the zenith. An official decision of using ACN: Methanol: Phosphate cradle pH-3 (30:25:45 %, v/v) (25 mM) as a convenient stage relied upon explicit

estimates like unbalanced factor, support time of the OLZ and FLX drugs, affectability of the procedure and cost. Affectability of the procedure was not actually recognized at 271 nm, however at 252 nm affectability was extended stunningly. Upkeep time of MFH and SPG was 2.36 and 3.39 min.

## ACKNOWLEDGEMENTS

The makers are thankful to Meditab Specialties Pvt. Ltd, (Daman) for giving Sitagliptin phosphate and Metformin hydrochloride as gift samples.

## REFERENCES

1. Goodman and Gilman's. The Pharmacological Basis of Therapeutics, McGraw-Hill, New Delhi, 11th edition. 2006;17.
2. Daharwal S. in Methods of estimation of multi-component formulations: A review. 2006;4(3).
3. Dong M. Modern HPLC for practicing scientist. A John Wiley, Sons Inc and Hoboken 2<sup>nd</sup> edition. 2007;194:217.
4. Jeffery G. In Vogel's textbook of quantitative analysis, ed. J. Basset, J. Mendham, R. Denney, Longman Scientific and Technical, London, 5<sup>th</sup> edition, 1999, ch.8, pp 220-227.
5. Skoog D. in Analytical chemistry – An Introduction, ed. D. West, Saunder college, 6<sup>th</sup> edition. 1994;25:689.
6. Sharma BK. Instrumental methods of chemical analysis. Goel publishing House, Meerut, 23<sup>rd</sup> Edn. 2004;7-8.
7. Kasture A. Pharmaceutical analysis, Nirali, Pune, 17<sup>th</sup> edition. 2009;2(7):48-57.
8. Snyder L. Practical HPLC Method Development, 2<sup>nd</sup> edition. 1997;6(9):233-265, 616-642.
9. McMaster M. In HPLC a practical user's guide, Wiley, New Jersey, 2<sup>nd</sup> edition. 2007;3:137-165.
10. Lee, Webb, a text book of Pharmaceutical analysis. 2008:43-48.
11. David Harvey. A textbook of Modern Analytical Chemistry. 2000;578.
12. Beckett AH and Stenlake JB. Practical Pharmaceutical chemistry, 4<sup>th</sup> Edn., Part –II, CBS Publishers and Distributors, New Delhi. 278-282.
13. Gennaro AR, Karen BM and Medwick T. Remington: The Science and Practice of Pharmacy, 19<sup>th</sup> Edn., Vol-I, The Mack Publishing Company, Pennsylvania. 1995;437-490.
14. Willard H. in Instrumental Methods of Analysis, ed. L. Merritt, J. Dean, F. Settle, CBS, New Delhi, 7<sup>th</sup> edition. 2002;617.
15. Ahuja S. in HPLC Method Development for Pharmaceuticals, ed. H. Rasmussen, Elsevier, London, 1<sup>st</sup> edition. 2007;8(2 & 16):13-42, 441-457..
16. Christen GD. Analytical Chemistry, fifth ed., John Wiley & Sons, Inc. 2001:505 Illet and Ripper, "Selectivity optimization in HPLC", In; Brown, R., Phyllis, Eligrushka, Advances in chromatography, 39, Marcel Dekker, Inc. 1998:264-65.
17. Sethi PD. HPLC-Quantitative analysis of pharmaceutical formulations. CBS publishers and Distributors, New Delhi. 2001;11.
18. Sethi PD. HPLC-Quantitative analysis of pharmaceutical formulations. CBS publishers and Distributors, New Delhi. 2001;5.
19. www. lab compliance.com.
20. USP30-NF25 (2007), the united state pharmacopoeia, The National FormularyUS Pharmacopoeia Convention Indc, Rockyvilley. 3413.
21. Indian pharmacopoeia, 2007.
22. Rangari S. Thin layer Chromatography of ibogaine from plant extract of Tebernantheiboga" J CPR. 2015;5(3):1565-1568.
23. Santhosha B. Validation method for Simultaneous Estimation of Metformin Hydrochloride and Vadagliptin by RP-HPLC In Bulk and Pharmaceutical dosage form. International Research Journal of Pharmaceutical applied science. 2012;2(3):22-28.
24. Patel C. Validated HPLC method for the Simultaneous Determination of Metformin HCl and Sitagliptin Phosphate in Marketed Formulation, International Journal of Analytical and Bioanalytical Chemistry. 2013;3(1):47-51.
25. Abula D. Analytical Method Development and Validation of Sitagliptin phosphate by RP-HPLC. Inernational Journal of Evolution of Bilayer Tablet of Metformin and Sitagliptin Phosphate International Pharmacy and Pharmaceutical science. 2012;4(2).
26. Jeyabalan G. Analytical Method Development and Validation of Sitagliptin phosphate in Pure and Tablet dosage form. J Applied Pharmaceutical Science. 2012;3(1):95-98.
27. Khan G. Simultaneous Estimation of Metformin and Sitagliptin in Tablet Dosage Form, Asian Journal of Biochemical and Pharmaceutical Research. 2011;2(vol-1):352-358.
28. Inamdar H. RP-HPLC Method for Simultaneous Determination of Metformin Hydrochloride, Rosiglitazone and Sitagliptin-Application to Comerciability Available Drug Products, International Journal of Pharmaceutical Sciences and Research. 2012;3(09):3267-3276.

29. Subhakar J. Development and validation of RP-HPLC Method for Simultaneous Determination of Validagliptin and Metformin hydrochloride in dosage form. *International Research Journal of Pharmaceutical Applied science*. 2012;(2):44-50.
30. Jadhav S. Development and Validation of RP-HPLC and HPTLC Methods for Simultaneous Estimation of Sitagliptin Phosphate and Metformin Hydrochloride in Bulk and Dosage form, *Indian Journal of Pharmaceutical Education and Research*. 2013;47(1):13-16.
31. Kumar S. Development and validation of Analytical Method for Estimation of Sitagliptin phosphate and Metformin Hydrochloride in Bulk and dosage form. *IJPER*. 2012;299.
32. Loni A. Method Development and Validation for Simultaneous Determination of Sitagliptin Phosphate and Metformin Hydrochloride by RP-HPLC in Bulk and Tablet Dosage Form, *Asian Journal of Pharmaceutical Sciences and Research*. 2012;2(8):23-37.
33. Shaymala M. Validation of RP-HPLC for Simultaneous Estimation of Sitagliptin Phosphate and Metformin Hydrochloride in Tablet dosage form *American Journal of Pharmaceutical - Tech and Research*. 2006;2(4):345-349
34. Narandra N. Method Development by Simultaneous Estimation of Sitagliptin Phosphate and Metformin Hydrochloride in Pure and Tablet dosage form by ultraviolet Spectroscopy *World J of Pharmacy and Pharmaceutical science*. 2012;1(4):392-1401.
35. Patil S. Development and Validation of a Stability Indicating RP-HPLC Method for Simultaneous Determination of Sitagliptin and Metformin in Tablet Dosage Form, *International Journal of Research in Pharmaceutical and Biomedical Sciences*. 2013;4(2):590-596.
36. Diwan P. Development of Stability Indicating RP-HPLC Method for the Determination of Sitagliptin Phosphate and Metformin HCl in Tablet Dosage Form, *International Journal of Pharmacy and Industrial Research*. 2012;2(3).
37. Sirisha R. RP-HPLC Method Development and Validation for Simultaneous Estimation of Metformin and Sitagliptin in Tablet Dosage Forms, *International Journal of Pharmaceutical Research and Analysis*. 2013;3(1):8-12.
38. Abdel S. Development and Validation of Spectrophotometric Method of Sitagliptin phosphate and simvastatin in Binary Mixture. *European Journal of chemistry*. 2012;3(4):447-454.
39. Sheetal S. Simultaneous UV-Spectroscopy method for Estimation of Sitagliptin phosphate and simvastatin in Tablet dosage form *International Journal of Pharmaceutical Research*. 2012;5(1):444-446.
40. Patil S. Development and Validation of Stability Indicating RP-HPLC Method for Simultaneous Determination of Sitagliptin and Metformin in Tablet Dosage Form, *International Journal Of Research in Pharmaceutical and Biomedical Sciences*. 2013;4(2):590-596.
41. Sumithra M. Development of RP-HPLC Method and its Validation for Simultaneous Estimation of Sitagliptin and Metformin, *International Journal of Pharmaceutical and Chemical Sciences*. 2012;1(1):360-364.